Anna Farago, MD, Oncology, Boston, MA, Dana-Farber Cancer Institute

AnnaFloraFaragoMD

Oncology Boston, MA

Hematologic Oncology

Clinical Fellow in Medicine, Dana-Farber Cancer Institute

Dr. Farago is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Farago's full profile

Already have an account?

Education & Training

  • Brigham and Women's Hospital
    Brigham and Women's HospitalFELLOWSHIP
  • Brigham and Women's Hospital
    Brigham and Women's HospitalRESIDENCY
  • Harvard Medical School
    Harvard Medical SchoolMEDICAL_SCHOOL

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 2010 - 2022
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Lectures

  • ATLANTIS: Global, randomized phase III study of lurbinectedin (L) with doxorubicin (DOX) vs. CAV or topotecan (T) in small-cell lung cancer after platinum therapy. 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
  • Safety and efficacy of combination olaparib (O) and temozolomide (T) in small cell lung cancer (SCLC). 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018

Press Mentions

  • Combining Forces in Small Cell Lung Cancer
    Combining Forces in Small Cell Lung CancerNovember 21, 2019
  • Potential New Treatment Strategy for Relapsed SCLC
    Potential New Treatment Strategy for Relapsed SCLCSeptember 11, 2019
  • PARP Inhibitor Combination Shows Activity in Small Cell Lung Cancer
    PARP Inhibitor Combination Shows Activity in Small Cell Lung CancerAugust 21, 2019
  • Join now to see all

Hospital Affiliations